Clinical trial

PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC

NCT07416058

Study summary

ClinicalTrials.gov

PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC

Design: INTERVENTIONAL · Status: NOT YET RECRUITING · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention QL1706 (bispecific antibody targeting PD-1 and CLTA-4) Find medicine records · Find other trials using this name

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2026-01-31

PhasePHASE2

Conditions

Lung Adenocarcinomaverified · MONDO: lung adenocarcinoma

Interventions

QL1706 (bispecific antibody targeting PD-1 and CLTA-4)DRUG

Sponsors & collaborators

Guangdong Association of Clinical Trialslead sponsor

Qilu Pharmaceutical Co., Ltd.collaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07416058 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.